secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001193125-26-056020
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma reports $728.9M cash, obicetrapib regulatory decisions expected 2H26
--------------------------------------------------------------------------------

- Regulatory decisions from EMA, UK, Switzerland for obicetrapib monotherapy & FDC expected in 2H26.
- Cash position $728.9M at Dec 31, 2025; net loss $203.8M for FY2025.
- Topline data from RUBENS Phase 3 trial (type 2 diabetes/metabolic syndrome) expected by year-end 2026.
- PREVAIL CVOT blinded event rate through initial 12 months tracking in line with BROADWAY.
- Plan to initiate Alzheimer's disease trial in 2026 based on positive biomarker data from BROADWAY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526056020/0001193125-26-056020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526056020/nams-20260218.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-056020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer